期刊文献+

利托那韦的合成工艺研究 被引量:4

Synthesis of ritonavir
下载PDF
导出
摘要 目的对利托那韦的合成工艺进行优化研究,以获得一条适宜于工业化生产的合成工艺路线。方法使用(2S,3S,5S)-2-胺基-3-羟基-5-(叔丁氧羰基胺基)-1,6-二苯基己烷的丁二酸盐作为起始原料,经过酰胺化、氨基脱保护和再酰胺化三步反应,最终制得目标产物利托那韦。结果经过相应的优化研究之后,最终成功地以较高的收率合成了高纯度的利托那韦产品(总收率57%,纯度>99%)。结论获得了一条较优的利托那韦合成工艺路线,该工艺路线具有高效、简洁以及绿色等特点,能够满足工业化生产的需要,具有广阔的应用前景。 Objective To optimize the synthesis of ritonavir,in order to obtain a suitable synthetic routes for industrial production. Methods Ritonavir was finally synthesized via three steps including amidation,deprotection of amine,amidation from (2S,3S,5S)-2-amino-3-hydroxy-5-(tert-butoxycarbonyl amino)-1,6-diphenyl hexane succinate.Results After the study of optimization,ritonavir was synthesized with high yield and high purity (overall yield 57%,purity 〉99%).Conclusions An efficient,simple,green synthesis route of ritonavir is available,which makes it suitable for industrial production.
出处 《安徽医药》 CAS 2015年第1期31-34,共4页 Anhui Medical and Pharmaceutical Journal
基金 安徽省研究生"千人培养计划"资助
关键词 利托那韦 HIV 蛋白酶抑制剂 工艺研究 ritonavir HIV protease inhibitor process research
  • 相关文献

参考文献10

  • 1杨文思,王洋.艾滋病治疗药物—HIV抑制剂作用机制及研究进展[J].现代生物医学进展,2012,12(23):4560-4562. 被引量:4
  • 2胡玉丽,刘朝霞.对AIDS患者疼痛的护理干预[J].中国艾滋病性病,2008,14(4):419-419. 被引量:4
  • 3徐洪根,何彩玉,汤君,程杰,柏俊.洛匹那韦合成工艺研究[J].安徽医药,2014,18(4):610-613. 被引量:5
  • 4Josbi A, Vron J/J, Unge J, et al. Design and synthesis of P1 P3 macrocyelic tertiary-alcohol-comprising HIV-1 protease inhlbi- torsi J]. J Med Chem,2013,56(22) : 8999 -9007.
  • 5Katende-Kyenda NL, Lubbe MS, Serfontein JHP,et al. Determining potential drug-drug interactions between lopinavir/ritonavir and other antiretrovirals and prescribed daily doses in a section of the private health care sector in South Africa[ J]. Afr J Pha Pharma- col,2013,7(41 ) : 2727 -2733.
  • 6Aspiroz EL, Cabrera Figueroa SE, Cruz R, et al. Toxicogenetics of lopinavir/ritonavir in HIV-infected European patients J ]. Person- alized Medicine ,2014, l 1 ( 3 ) :263 - 272.
  • 7Bellani P, Frigerio M, Castoldi P. Process for the synthesis of ritonavir: US,6407252B1 [ p]. 2002 -06 - 18.
  • 8靳立人,许志杰,蒋洪平.一种合成利托那韦的方法:中国,1247554[P].2004.12.15
  • 9Bose P, Biswas S, Rathore RS. A process for the synthesis of 2-a- mino-5-protected amino-3-hydroxy-1,6-diphenylhexant or a salt thereof-an intermediate of antiviral drugs : WO, 2006/090 264 [P].2006 -08 -31.
  • 10Bauer J, Spanton S, Henry R, et al. Ritonavir: an extraordinary, ex- ample of eanformational polymorphism [ J ]. Pharm Res, 2001 , 18 (6) :859 -866.

二级参考文献26

  • 1姜辉,李俊,胡成穆.艾滋病治疗策略的研究进展[J].安徽医药,2006,10(11):803-805. 被引量:1
  • 2Fauci AS. The human immunodeficiency virus: infectivity and mechanisms ofpathogenesis[J]. Science,1988,239(4840):617-622.
  • 3Zhang L, Huang Y, He T, et al. HIV-1 subtype and second-receptor use [J]. Nature,1996,383(6603):768.
  • 4Weiss RA. How doos HIV cause AIDS?[J]. Science,1993,260(5112): 1273-1279.
  • 5Balzarini J. Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunocleficiency virus activity of nucleoside reverse transcriptase inhibitors[J]. Pharmacol Ther,2000,87(2-3):175-187.
  • 6Turner B J, McKee-Nelsen L, Fanning TR, et al. Prevention of vertical HIV transmission with zidovudine: projected impact of HIV testing and prenatal care[J]. AIDS Care,1997,9(5):577-588.
  • 7Lewis W, Day B J, Copeland WC. Mitoehondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective [J]. Nat Rev Drug Discov,2003,2( 10):812-822.
  • 8Pedersen OS, Pedersen EB. Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom[J]. Antivir Chem Chemotlaer, 1999,10(6): 285-314.
  • 9Buckheit RW Jr, Watson K, Fliakas-Boltz V, et al. SJ-3366, a unique and highly potent nounucleoside reverse transeriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2[J]. Antimicrob Agents Chemother,2001,45(2):393-400.
  • 10Galina N, Nikolenko, Krista A, et al. A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transc- riptase Inhibitors[J]. J Virol,2010,84(10): 5238-5249.

共引文献11

同被引文献7

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部